IMR Press / EJGO / Special Issues / 1590722031268

Topic Collection "Current Novel Treatment of Patients with Ovarian Cancer"

Submission deadline: 31 December 2022
Special Issue Editors
  • Samir A. Farghaly, MD, PhD
    The Weill Cornell University Medical College, New York, NY, USA
    Interests: Gynecological cancers minimally invasive surgery; Ovarian cancer targeted therapy; Ovarian cancer precision medicine; Immuno-oncology; Genomic profiling of ovarian cancer; Ovarian cancer biomarkers
    Special Issues and Topics in IMR Press journals
  • Scott M. Eisenkop, MD
    Women's Cancer Center, Southern California, 4835 Van Nuys Blvd, Suite 208, Sherman Oaks, CA 91403, USA
    Interests: Hysterectomy; Lymph node dissection; Robot assisted surgery
    Special Issues and Topics in IMR Press journals
Special Issue Information

Dear Colleagues,

Ovarian cancer is the seventh most common deathly cancer in women and accounted for almost 300,000 new cases, and almost 200,000 deaths annually worldwide in 2018.   In 2020, there will be approximately 21,750 new cases of ovarian cancer diagnosed and 13,940 ovarian cancer deaths in the USA. Primary debulking/cytoreductive surgery associated with a platinum/paclitaxel –based chemotherapy, is the standard care within treatment of advanced ovarian cancer (FIGO stage III and IV).  The surgery could be achieved through open ultra-radical laparotomy surgery, laparoscopy, or robot-assisted laparoscopic surgery.  Due to its late presentation, often stage III or IV, the prognosis is poor. Notwithstanding the good initial response to primary therapy, optimal debulking followed by the two-drug combination of carboplatin plus paclitaxel, responses are generally short-lived, and the clinical outcome is still unsatisfactory with median progression free survival rates from 16 to 21 months. Platinum resistant patients are often offered other chemotherapeutics, including doxorubicin, gemcitabine or topotecan monotherapy with PFS rates of 3-4 months. There is a pressing need to identify more efficient therapies. Anti-angiogenesis therapeutics, Bevacizumab cediranib, and trebananib offers relatively good results in both primary and recurrent ovarian cancer.  Attempts to optimize chemotherapy have included weekly scheduling of paclitaxel and intraperitoneal chemotherapy. Trials using angiogenesis inhibition and poly-ADP ribose polymerase (PARP) inhibitors that have been FDA-approved for maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: olaparibrucaparib, and niraparib show an advantage in progression free survival. In addition, Trabectedin combined with liposomal doxorubicin play a role in patients with intermediate platinum sensitive disease. Hyper thermic intraperitoneal chemotherapy (HIPEC) and chemo-immunotherapy may become a promising therapy for the treatment of ovarian cancer.  This publication is most timely, as our current knowledge and understanding of screening, the pathophysiology of ovarian cancer, molecular aspects of cancer progression and metastasis, and advances in minimally invasive surgery technology, has led to significant improvement of the relevant treatment modalities, including promising targeted and personalized therapy.

Prof. Dr. Samir A. Farghaly and Dr. Scott M. Eisenkop

Guest Editors

Ovarian Cancer
Epithelial Ovarian Cancer
Optimal Debulking Surgery
Platinum-resistant Ovarian Cancer
PARP Inhibitors
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.

Back to top